
Lilly wins appeal for donanemab, drug to be reconsidered for NHS
Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use. The National Institute for Health and Care Excellence (NICE) published the outcome for Lilly’s appeal, after final draft guidance had not recommended NHS reimbursement of donanemab for the treatment of mild cognitive… Read More











